We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Patent Board Sides With Patent Owner In Final Written Decision

Mealey's (February 8, 2018, 8:54 AM EST) -- ALEXANDRIA, Va. — A patented method for treating inflammatory autoimmune diseases with a high concentration subcutaneous methotrexate formulation was confirmed as patentable on Feb. 7 by the Patent Trial and Appeal...
To view the full article, register now.